Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|April 1, 2004
- Volume 0 0
TampAlerT
Advertisement
TampAlerT, manufactured by Medi- Dose/EPS, Inc (Ivyland, Pa), is a unique system that allows practitioners to package liquids, solids, or powders in unit doses with tamper-evident seals. TampAlerT is perfect for legend drugs and controlled substances, inpatient, or afterhours dispensing. It is available in vial sizes from 15 mL to 120 mL in natural or white ultraviolet-inhibitant polyethylene with regular or child-resistant caps. For more information: 888-TAMPALERT or 800-523-8966 www.medi-dose.com
Articles in this issue
over 22 years ago
RxPRODUCT NEWS PROFILE: Caduetover 22 years ago
COMPOUNDING HOTLINEover 22 years ago
Case Studiesover 22 years ago
Buddies Are Good for the Heartover 22 years ago
Low-Fat Diet Shows Promise for Prostate Cancerover 22 years ago
Rage Is Connected to Stroke Riskover 22 years ago
InnoLetover 22 years ago
Colace/Peri-Colaceover 22 years ago
Low Testosterone Is Linked with Alzheimer's Diseaseover 22 years ago
Wound Care in an Aging Population: Special ConsiderationsAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5